Loading clinical trials...
Loading clinical trials...
A Retrospective Study to Evaluate the Clinical-Biologic Characteristics and Outcome of Patients Treated in Italy According to the Ibrutinib-Named Patient Program for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Conditions
Interventions
Ibrutinib
Locations
47
Italy
U.O.C. Ematologia e Terapia Cellulare - Ospedale "C. e G. Mazzoni" di Ascoli Piceno
Ascoli Piceno, Italy
U.O.C di Ematologia P.O. "S.Giuseppe Moscati" - 2° piano
Aversa, Italy
UO Ematologia con trapianto-Università degli Studi di Bari Aldo Moro
Bari, Italy
Istituto di Ematologia "Lorenzo e A. Seragnoli" - Università degli Studi di Bologna - Policlinico S. Orsola - Malpighi
Bologna, Italy
Spedali Civili - Brescia - Azienda Ospedaliera - U.O. Ematologia
Brescia, Italy
Divisione di Ematologia Ospedale A. Perrino
Brindisi, Italy
Start Date
March 1, 2016
Primary Completion Date
October 1, 2018
Completion Date
October 3, 2018
Last Updated
September 13, 2021
NCT07277231
NCT05006716
NCT06859424
NCT01804686
NCT05254743
NCT05371808
Lead Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions